PKO Investment Management Joint Stock Co Boosts Stake in IQVIA Holdings Inc. (NYSE:IQV)

PKO Investment Management Joint Stock Co increased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 180.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,000 shares of the medical research company's stock after purchasing an additional 4,500 shares during the quarter. PKO Investment Management Joint Stock Co's holdings in IQVIA were worth $1,234,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Howard Capital Management Inc. boosted its holdings in IQVIA by 4.9% in the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after purchasing an additional 54 shares during the last quarter. Continuum Advisory LLC boosted its stake in IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after acquiring an additional 64 shares during the last quarter. ST Germain D J Co. Inc. boosted its stake in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the last quarter. New York Life Investment Management LLC boosted its stake in IQVIA by 0.4% during the 4th quarter. New York Life Investment Management LLC now owns 23,086 shares of the medical research company's stock valued at $4,537,000 after acquiring an additional 81 shares during the last quarter. Finally, Zions Bancorporation N.A. lifted its position in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after purchasing an additional 85 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Trading Up 0.3%

IQVIA stock traded up $0.53 during trading hours on Wednesday, hitting $154.63. The company had a trading volume of 1,667,170 shares, compared to its average volume of 1,628,015. The company has a debt-to-equity ratio of 2.19, a quick ratio of 0.82 and a current ratio of 0.82. The firm has a market cap of $26.75 billion, a P/E ratio of 21.07, a P/E/G ratio of 1.69 and a beta of 1.28. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a 50-day moving average price of $147.84 and a two-hundred day moving average price of $176.89.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. IQVIA's quarterly revenue was up 2.5% on a year-over-year basis. During the same period last year, the business earned $2.54 earnings per share. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on IQV. Redburn Partners set a $188.00 price target on shares of IQVIA in a research report on Friday, May 23rd. Robert W. Baird cut their price objective on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Citigroup reiterated a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. HSBC downgraded IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Finally, Barclays dropped their price target on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 7th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.